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Abstract: 33 
Antibodies are highly functional glycoproteins capable of providing immune protection 34 
through multiple mechanisms, including direct pathogen neutralization and the engagement 35 
of their Fc-portions with surrounding effector immune cells and immune components that 36 
induce anti-pathogenic responses. Small modifications to multiple antibody biophysical 37 
features induced by vaccines and other therapeutic regimens ca  ignificantly alter functional 38 
immune outcomes, though it is difficult to predict which combinations confer protective 39 
immunity.  In order to give insight into the highly complex and dynamic processes that drive 40 
an effective humoral immune response, h re we discuss recent applications of “Systems 41 
Serology”, a new approach that uses data-driven (also called ‘machine learning’) 42 
computational analysis and high-throughput experimental data to infer networks of important 43 
antibody features associated with protective humoral immunity and/or Fc functional activity.  44 
This approach offers the ability tounderstand humoral immunity beyond single correlates of 45 
protection, assessing the relative importance of multiple biophysical modifications to 46 
antibody features with multivariate computational approaches. Systems Serology has the 47 
exciting potential to help identify novel correlates of protection from infection and may 48 
generate a more comprehensive understanding of the mechanisms behind protection, 49 
including key relationships between specific Fc functions and antibody biophysical features 50 
(e.g. antigen recognition, isotype, subclass and/or glycosylation events). Reviewed here are 51 
some of the experimental and computational technologies available for Systems Serology 52 
research and evidence that the application has broad relevance to multiple different infectious 53 
diseases including viruses, bacteria, fungi and parasites. 54 
 55 
Word count: 3955 words excluding abstract, references, tables and figure legends 56 
Introduction:  57 
In 1776, Edward Jenner inoculated a child with matter from a cowpox sore on a milkmaid’s 58 
hand, and noted that the child was then protected against smallpox infection 1.  This event 59 
was the beginning of modern-day vaccines, which have transformed society and saved 60 
millions of lives. As the success of vaccines has been wonderfully beneficial, it has 61 
influenced our approach to the study and treatment of infectious diseases.  Vaccination 62 
methods today remain largely based on broad single-target approaches, similar to those first 63 
employed by Jenner more than 200 years ago 2. More specifically, many of the currently 64 
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binding antigen-specific antibodies or neutralizing antibodies being the most common 66 
assessment for protection against pathogens including polio, influenza, yellow fever, 67 
hepatitis, HPV, pertussis and pneumococcus 3, 4
 72 
. However, for many of the world’s deadliest 68 
pathogens, including ebola, malaria and HIV, the development of an effective vaccine has 69 
been hindered largely due to our inability to elucidate the immune correlates of protection by 70 
traditional approaches. 71 
The importance of Fc-mediated functional antibodies for protection and control of 73 
diseases 74 
Antibodies (Abs) are highly functional glycoproteins that are a vital immune component for 75 
protection and control of infectious diseases. For a number of vaccines (e.g., polio, influenza, 76 
tetanus, etc.) neutralizing Abs against the pathogen or toxins have been identified as the 77 
correlates of protection. Interestingly, for many other vaccines (eg., Hepatitis A), total 78 
pathogen-specific binding Abs have been identified as correlates of protection, yet the 79 
specific mechanisms behind these pathogen-specific binding Abs remain unclear 4. Beyond 80 
neutralization, Abs are capable of providing immune protection through multiple additional 81 
mechanisms, via engagement of their Fc (Fragment crystalizable) portions. To date, only one 82 
licensed human vaccine (Pneumococcus) has identified Fc-mediated functional Abs as a 83 
correlate of protection 5.  However, there is growing evidence that supports the role for Fc 84 
functional Abs in the control of a wide range of pathogens including bacterial, viral, fungal 85 
and parasitic infections. These Abs have the unique capacity to bridge the gap between innate 86 
and adaptive immunity, by harnessing both the specificity of the humoral adaptive immune 87 
response provided by the Ab’s Fab (Fragment antigen-binding) region, which recognizes the 88 
pathogen, as well as by rapidly activating Fc Receptor (FcR) innate immune effector cell 89 
responses (e.g., complement) via the Ab’s Fc region. Activation can induce a range of anti-90 
pathogenic immune responses including but not limited to Ab dependent cellular cytotoxicity 91 
(ADCC), Ab dependent cellular phagocytosis (ADCP), Ab dependent complement activity 92 
and Ab dependent cytokine, chemokine and/or enzyme release (Figure 1).  Importantly, FcR 93 
innate immune effector cells are abundantly located throughout the body and can be recruited 94 
by these non-neutralizing Abs without any need for prior antigen sensitization 6, 7
 96 
. 95 
Emerging evidence from multiple infectious disease models strongly suggest that functional 97 
Abs are important for mediating control and/or protection against viral, bacterial, fungal and 98 
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(e.g., HSV 9) pathogens have evolved to encode proteins that specifically protect them from 100 
Fc mediated Ab functions 10
 105 
, further supports the notion that these non- eutralizing anti-101 
microbial properties of Abs play a vital role in protection from infectious diseases. Examples 102 
of the importance of Fc functional Abs in the control and/or protection of different pathogens 103 
are summarized in Table 1. 104 
Lessons learned from HIV Vaccines Trials  106 
Despite three decades of intense research, the development of an effective vaccine against 107 
HIV continues to produce lackluster results. To date, only one human Phase III HIV vaccine 108 
trial has shown a modest, but significant level of efficacy (31.2%) 11.  Surprisingly, this 109 
RV144 vaccine trial did not induce CD8+ T cell cellular immunity, broadly neutralizing Ab 110 
responses or high binding antigen-specific Ab levels 11, 12. Instead immune correlates analysis 111 
identified the importance of Abs targeting the V1V2 region of the HIV envelope and Ab112 
dependent cellular cytotoxicity (ADCC) activity, in the absence of high levels of IgA 12, 13. 113 
Follow-up analyses discovered additional features of the humoral immune response 114 
associated with protection, including the preferential induction of IgG3 responses 14, 15, which 115 
were able to mediated multiple Ab effector functions including ADCC, Ab mediated cytokine 116 
and chemokine production from NK cells and Ab mediated cellular phagocytosis (ADCP) in 117 
a coordinated manner, otherwise known as polyfunctional Ab immunity 15
 119 
.  118 
Furthermore, multiple non-human primate (NHP) SIV/SHIV vaccine studies have recently 120 
been conducted highlighting the complexity of potential correlates of protection. 121 
Administration of an adenovirus vector 26 (AD26) prime followed by an envelope protein 122 
boost in NHP was able to provide 50% protection against repetitive SIV challenges 16. 123 
Interestingly, protective efficacy was not associated with a neutralization, but instead 124 
polyfunctional Ab immune responses (incorporating six different Ab Fc functions) were 125 
associated with protection 16. Similarly, other NHP studies have correlated both ADCP and 126 
Ab dependent complement deposition (ADCD) with protective efficacy 17. More recently, 127 
partial protection from SHIV infection was observed in NHP when administered with a 128 
canary pox prime (ALVAC)/ recombinant pentavalent velope protein vaccine 18. Multiple 129 
humoral immune correlates were associated with decreased ri k of infection, including 130 
plasma Ab binding to HIV-infected cells, ADCC Ab titers, NK cell-mediated ADCC and Ab 131 
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These recent human and NHP HIV vaccines studies have highlighted our limited 134 
understanding of humoral immune responses and challenges us to shift our analysis of 135 
potential humoral immune correlates from being a univariate or “one component at a time” 136 
paradigm (e.g., neutralization or total Ab binding titers alone) to a multivariate “many 137 
components at once”, or systems concept for design of new strategies for more difficult to 138 
vaccinate diseases, based on systems-l vel properties of humoral immunity or as it has been 139 
more simply termed “Systems Serology” 19, 20
 141 
.   140 
Complexity of functional antibodies: 142 
Upon vaccination or infection by a pathogen, the humoral immune response aims to produce 143 
diverse, highly polyclonal Abs to target the foreign pathogens. The functional capacity of the 144 
humoral immune response is determined by multiple cumulative factors defined by an Ab’s 145 
biophysical features that are modulated by genetic, molecular and environmental factors 146 
(Figure 1 and summarized in Table 2). These include the ability of the Ab to effectively 147 
recognize the foreign antigen dictated by an Ab’s Fab (Fragment antigen-binding) region, 148 
along with the capacity of the Ab to engage with surrounding Fc effector cells and immune 149 
components (modulated by the Ab Fc-portion). 150 
 151 
Despite an Ab’s Fc region often being referred to as the ‘constant’ region, the Fc is 152 
surprisingly diverse, with subtle modifications having the capacity to significantly alter 153 
engagement and affinity to FcRs and/or other Fc binding immune components, including 154 
complement and mucins. These include differences in mmunoglobulin isotypes: IgA, IgD, 155 
IgE, IgG and IgM, of which IgG is the most predominant immunoglobulin present in healthy 156 
human plasma 21. While each isotype has their own characteristic properties and functions, 157 
IgG is most commonly associated with mediating Fc effector responses, although IgA 22, IgM 158 
23 and IgE 24 also induce vital roles in protective immunity by activating their respective FcR 159 
innate immune cells and/or complement e.g. the importance of IgE and activation of Fc-160 
epsilon R effector cells for protection against parasitic infections has been well documentd 161 
25. As an additional level of complexity, immunoglobulin isotypes also express different 162 
subclasses for example: IgG consists of four subclasses, IgG1, IgG2, IgG3 and IgG4, each 163 
binding with varying affinity to different FcγRs 26, 27
 165 
. 164 
Beyond subclass, Fc function is also determined by changes in Ab glycosylation, particularly 166 
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which can have important functional consequences by influencing the affinity of IgG’s for 168 
their respective FcγRs on effector cells and complement proteins. Complete aglycosylation of 169 
an Ab abolishes FcγR and complement binding 30, whereas the presence or absence of 170 
particular glycan forms can alternatively inhibit or enhance Fc functionality 31, 32. Table 2 171 
summarizes the many different features of the antigen-Fab Ab and Ab Fc-FcR interactions 172 
that can modulate Fc functionality and lists example assays available to allow for the in-depth 173 
assessment of these Ab features. Systems Serology therefore aims to use high t roughput 174 
assays, to collate a holistic assessment of all Ab features that can potentially modulate Fc 175 
functionality, providing us with a detailed portrait, or humoral immune “signature” associated 176 
with protection or control of infection. While many of these assays have been developed and 177 
optimized for use predominately against viruses (especially HIV 18, 19), these assays have the 178 
potential to be adapted and optimized for examination of other infectious diseases 33
 180 
.  179 
Generating insights into the complexity of the humoral response: Systems Serology 181 
Given the complexity of Ab biophysical features, a quantitative, systems approach will  182 
provide new perspective and insight into key quantitative relationships between the features 183 
that characterize a vaccine response, confer protection, or underpin a desired functional 184 
response.  A quantitative understanding of relationships between Ab biophysical features, Fc 185 
functional responses and clinical outcomes could enable design of new vaccine regimens 186 
specifically targeted to enhance or suppress key parts of this system; altering overall network 187 
humoral immunity rather than a single component (Figure 1B).  Though advancements in 188 
experimental technologies now enable the measurement of large numbers of biophysical Ab 189 
features (detailed in Table 2), a major challenge still remains in determining the relative 190 
importance of alterations in these Ab features that occur with vaccination, and key 191 
quantitative relationships that drive a desired immune response or c nfer protection. “Data-192 
driven” modelling approaches 34 (also called “machine learning” approaches) hold great 193 
promise for better understanding Ab systems, as they enable integration of high-throughput 194 
experimental data to mathematically identify relationships between Ab biophysical features 195 
that are associated with important functional outcomes, vaccine regimen, or 196 
protection/control of infection (Figure 2).  These approaches can be applied as useful 197 
hypothesis-generating tools for new systems-level mechanisms involving multiple Ab 198 
features, and have the potential to accelerate our understanding of the humoral immune 199 
system by helping to define areas of interest for further experimental testing and additional 200 
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transcriptional signatures correlated with vaccine response has been demonstrated in a wide 202 
range of vaccinology applications 35-37
 207 
. However many of these previous studies have 203 
specifically focused on identifying genetic and transcriptional correlates of vaccine 204 
protection, especially for cellular immunity. In contrast, application of Systems Serology 205 
instead aims to focus upon gaining insights o functional humoral immunity.  206 
 208 
 209 
Data-driven tools: overview and examples 210 
Data-driven models have the potential to provide both better classification of vaccine 211 
responses (e.g., between protective and non-protective vaccines) as well as give systems-212 
level insight into networks of Ab biophysical features involved in important functional 213 
responses. Altogether, they are able to generate a valuable network “picture” (Figure 1B) of 214 
key events that may contribute to a specific functional immune response or clinical outcome. 215 
In general, all data-driven approaches involve analysis of a large data set (‘X’: Figure 2). In 216 
the case of Systems Serology, this may include measurements of the Ab’s biophysical 217 
features (e.g.,. Ab Fab recognition, Ab isotype, glycosylation, Fc receptor etc.; detailed in 218 
Table 2) believed to contribute to a particular outcome (i.e. functional response, vaccine 219 
regimen, or protection).  A subset of data-driven modelling approaches (including principal 220 
component analysis (PCA) and correlation networks) only employ this X data set, searching 221 
for significant multivariate relationships between measured features. This subset of 222 
approaches is considered “unsupervised” in that they evaluate relationships between features 223 
in X without information about an outcome. The strength of unsupervised approaches lies in 224 
the ability to search for features involved in the differentiation of outcomes in a completely 225 
unbiased way. Systemic, unbiased, examination of broad Ab profiles provides us with a more 226 
comprehensive understanding of the mechanisms behind specific functions, potentially 227 
revealing novel correlates between Ab features and functions that would not normally be 228 
identified by traditional approaches. 229 
 230 
Other data-driven approaches are considered “supervised” (including partial least squares 231 
discriminant analysis (PLSDA), partial least squares regression (PLSR) and decision trees, 232 
Figure 2), as they identify key relationships in X that are related to an important functional or 233 
clinical outcome (“Y”; e.g., functional response, vaccine regimen, or clinical outcome) 234 
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networks or systems of immune parameters driving a response, because they identify direct 236 
relationships between the two. Both unsupervised and supervised approaches are useful in237 
Systems Serology research, depending on the question being asked and nature of the data. 238 
One major advantage of all data-driven approaches is integration, or the ability to merge 239 
disparate data sets into a whole. By combining measurements from different sources into the 240 
same model, quantitative relationships between biophysical features associated with a clinical 241 
or functional outcome can be linked across experimental assays, tissue compartments, and 242 
time. Below we give examples of specific data-driven approaches that have been applied in 243 
Systems Serology research. In each case, we leave detailed mathematical descriptions to 244 
other published work, but highlight applications, advantages and limitations of each in the 245 
context of Systems Serology use.  246 
 247 
Unsupervised approaches: 248 
Perhaps the simplest way to visualize relationships between many different measured 249 
parameters is via the construction of c rrelation networks (Figure 2) 19, 38. These diagrams 250 
allow for the visualization of significant correlative relationships between paired measured 251 
features of interest. These networks can be created by first computing either the Pearson 252 
(parametric) or Spearman (non-parametric) correlation coefficient for each pair of measured 253 
variables. Relationships across all features can then be visualized via either a web-like 254 
structure or a heat map that indicates the direction and strength of each significant 255 
correlation.  The main advantage of correlation networks is that they are easy to create and 256 
interpret, and thus often give useful insight into potential mechanistic relationships between 257 
features.  One drawback is that they are unsupervised, and do not directly relate identified 258 
correlative relationships to a clinical or functional outcome of interest (Y). Therefore they 259 
have little use as predictive tools. Additionally, only pairwise relationships between measured 260 
features are considered; thus, true multivariate signatures involving three or more measured 261 
features are unattainable. This approach has been used previously to examine Ab network 262 
connectivity between Ab biophysical features and functions a sociated with the humoral 263 
response elicited by four different HIV vaccines (VAX003, RV144, HVTN204, and 264 
IPCAVD001) 19.  Vastly different network topographies or ‘humoral signatures’ were 265 
observed between the different vaccines trials and were able to highlight important 266 
mechanisms behind the moderately protective RV144 trial. More specifically, IgG1 and IgG3 267 















This article is protected by copyright. All rights reserved 
ADCD indicating their importance in modulating multiple Fc functions, while these 269 
interactions were not observed for the other non-efficacious vaccine trials. 270 
 271 
 272 
Principal component analysis (PCA) 39 is an unsupervised approach that can be used to 273 
determine signatures of measured features that account for the most variation between 274 
samples, in a set of measured features. For example, given dataset ‘X’ (Figure 2) containing 275 
measurements of Ab biophysical features, PCA identifies orthogonal, linear combinations 276 
(‘signatures’) of these measured features (termed “Principal Components”) that account for 277 
the most variation in the data, without any information about functional or clinical outcomes 278 
(Y).  Both advantages and disadvantages of PCA arise from the fact that it is an unsupervised 279 
approach – the algorithm receives no information about the outcome. This is advantageous, in 280 
that response differences can be visualized in an unbiased way, but disadvantageous in that it 281 
is not inherently hypothesis-driven.  While the identified principal components represent 282 
signatures of measured features that account for the most variation in the data, they are not 283 
specifically identified to discriminate between outcomes of interest,  as a functional or 284 
clinical response (Y) is not included in the model. Thus, they can give insight into important 285 
relationships between measured features, but they cannot directly predict how those features 286 
are associated with a functional or clinical outcome. Previously Systems Serology application 287 
of PCA applied to Mycobacterium tuberculosis serology studies were able to identify the 288 
importance of Ab glycosylation in distinguishing latent from active infection 33
 290 
. 289 
Supervised approaches: 291 
Partial least squares discriminant analysis (PLSDA) and partial least squares regression 292 
(PLSR) 40, 41 are supervised methods that identify signatures of measured features (X) 293 
quantitatively related to a functional or clinical outcome (Y) (Figure 2). Thus, both PLSDA 294 
and PLSR require input of both a data set of measured Ab features (X), as well as a measured 295 
outcome (Y). PLSDA and PLSR are differentiated by the fact that in PLSDA, Y contains a 296 
discrete class or label information (e.g.,vaccine 1, vaccine 2, etc.)  for each outcome, while Y 297 
for PLSR contains continuous numeric data (e.g., ADCC measurements that can range from 298 
0-100% cytotoxicity). Y is often a single column of data (e.g., only 1 outcome variable), but 299 
it can also be a matrix with multiple columns in situations for which there are several 300 
outcomes of interest. These algorithms determine orthogonal linear combinations 301 
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outcomes (Y). Each sample can then be scored and plotted on these signatures (termed ‘latent 303 
variables’) to determine model accuracy for predicting clinical outcome based on measured 304 
features. Each identified latent variable (signature), contains ‘loadings’, or specified amounts 305 
of each of the measured features. PLSDA and PLSR are especially useful for hypothesis-306 
driven Systems Serology research as they specifically search for signatures directly 307 
associated with an outcome (in contrast to PCA, which only evaluates overall variation in the 308 
data set (X)). An important consideration in using PLS algorithms is to ensure models are not 309 
‘overfit’  40, i.e. that the model contains only information about important underlying 310 
relationships rather than  including random error or noise. This can be avoided by performing 311 
cross-validation (reviewed for PLSDA in 40), whereby a smaller portion of the data is 312 
reserved to test a model generated by majority of the data. The ability of the mod l to 313 
accurately predict each sample in the test set can then be used to calculate cross-validation 314 
error, a measure of the model’s predictive ability. If cross-validation error is high, the model 315 
can be improved by performing ‘feature selection’ to remove features that contribute to 316 
random error. There are a number of different feature selection algorithms that may be used 317 
depending on the nature of the data set, ome examples of these include use of variable 318 
importance projection (VIP) scores 42 and the least absolute shrinkage and selection operator 319 
(LASSO) 43, 44
 326 
. One key advantage of PLS approaches for Systems Serology research is that 320 
loadings on latent variables of a feature-selected model can give great insight into co-varying 321 
serological features that are most involved in differentiating a functional or clinical outcome. 322 
In other words, the “minimum signature” that best defines a vaccine response can give a 323 
picture of key Ab features that would be best used to reconstruct the system (Figure 1B) for 324 
theoretical analysis.   325 
The application of PLSDA/PLSR analysis has been successfully applied in a wide range of 327 
Systems Serology settings, including to identify humoral immune correlates of the 328 
moderately protective human HIV RV144 vaccine trial, in non-human primate SIV/SHIV 329 
vaccine studies, and to examine the humoral responses induced by topical anti-retrovirals for 330 
pre-exposure prophylaxis following HIV infection 18, 19, 43, 45. In the study of topical anti-331 
retrovirals for pre-exposure prophylaxis following HIV infection 43, a PLSDA model used 332 
with LASSO feature selection identified a signature of 7 measured Ab features that 333 
differentiated women in the topical anti-retrovirals and placebo groups with 77% cross-334 
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specific Ab signature including measurements from different time points (6 and 12 months) 336 
and tissue compartments (plasma and cervicovaginal lavage). Individual Ab measurements 337 
we unable to differentiate between groups. Altogether this illustrates the utility of PLSDA for 338 
differentiating functional or clinical outcomes and for integrating Ab measurements to 339 
identify new hypotheses for mechanisms that may vary over time or tissue compartments.  340 
 341 
 342 
Decision trees 46 38 (Figure 2) provide unique insight into humoral responses in that they are 343 
easy to interpret, and can give useful information about the hierarchy of importance and 344 
critical ranges (e.g.,. concentration, binding affinity) of measured Ab features for a particular 345 
functional or clinical outcome. For these reasons, they can be especially useful for giving 346 
insight into potential mechanistic relationships between measured serological features. A 347 
decision tree algorithm works by performing a series of binary tests on the data set of 348 
measured Ab features (X), to split samples into groups based on the functional or clinical 349 
outcome (Y). The specific binary test performed is selected by the user, and called a ‘split 350 
criterion’ 46. Each split further purifies samples based on functional or clinical outcomes of 351 
interest (e.g., vaccine 1 vs. vaccine 2 vs. vaccine 3, etc.; Figure 2). The result is a tree-like 352 
structure that illustrates the hierarchy of importance of measured features based on outcome, 353 
with specific measurement ranges required for each node selected by the algorithm. As with 354 
other supervised approaches, an important consideration in using decision tree algorithms is 355 
cross-validation to prevent overfitting (described above). If cross-validation determines a 356 
decision tree is overfit, ‘pruning’ may be used to improve the model, whereby peripheral 357 
branches of the tree are removed if they contribute little to classification. More detailed 358 
information on decision tree cross-validation and pruning is reviewed in 46
 360 
.   359 
 361 
Future Outlook 362 
While the data-driven models used in current Systems Serology applications ffer the 363 
exciting opportunity to integrate high-t roughput data to identify key Ab features associated 364 
with a protective immune response, insight is still limited to multivariate statistical 365 
associations, without quantitative understanding of true cause-effect relationships that 366 
underpin mechanistic function. While carefully planned experiments based on data-driven 367 
models give some insight in this direction, they too are limited. Other quantitative approaches 368 
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beyond statistical associations and towards a qu ntitative systems-level understanding of 370 
mechanism. This will require use of equation-based methods, also called “theory-driven” 371 
approaches, where mathematical models are constructed based on prior knowledge of a 372 
system. Data-driven models can provide the underlying framework for these models – used to 373 
decide key parameters that should be included for a given question, boundaries and important 374 
input/output. Once constructed, these theory-driven models will provide a valuable 375 
hypothesis-testing tool, lending insight into 1) the importance of key Ab parameters in the 376 
formation of immune complexes and 2) the relative importance and synergistic effects of 377 
multiple Ab alterations involved in a functional or clinical outcome. These types of 378 
approaches have already been employed to optimize the design of Abs that trap viruses in 379 
mucus of the female reproductive tract, determining optimal quantitative ranges of Ab 380 
binding affinities that maximize both virion binding and Ab mobility in mucus 47
 382 
.   381 
Clearly Systems Serology technologies, both experimental assays and the application of 383 
analytical technologies are still in their infancy. Over time, high-throughput asays to assess 384 
biophysical Ab features and functions will continue to be developed and improved, 385 
encapsulating a wider range of infectious diseases and allow for the examination of Ab 386 
features and functions relevant to different tissue compartments and locations. Furthermore, 387 
Systems Serology applications can potentially be expanded to address other diseases 388 
associated with humoral immunity, including autoimmune diseases and selective cancers. 389 
There is no doubt that Systems Serology will continue to evolve to capture broader 390 
applications providing us with an increasingly comprehensive understanding of protective 391 
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Figure 1: Dynamic complexity of the humoral immune response 408 
A). The functional capacity of the humoral immune response is determined by complex 409 
biophysical antibody features including i). the pathogen being targeted and the ability of the 410 
antibody’s Fab to recognize different antigens, ii). an antibody’s Fc region's diversity which 411 
in turn can modulate the antibodies capacity to engage with iii). Fc Receptor/immune 412 
molecules and iv). availability of the Fc Receptors on different effector cells/immune 413 
molecules in the surrounding environment. B)  The combination of the pathogen targeted 414 
(e.g. infected cell versus small infectious particles) and binding by an Ab's Fab determines 415 
opsonisation, neutralization and immune complex formation. The composition of the Fc-416 
regions of these Abs can in turn modulate the functional immune response by surrounding 417 
effector cells/immune molecules potentially inducing a range of functions includig but not 418 
limited to ADCC, Ab mediated secretion of cytokines, Ab mediated enzyme release/NET 419 
(neutrophil extracellular trap) formation, Ab dependent phagocytosis, Ab mediated 420 
complement activity, mucus trapping etc. dependent on the cellular Fc receptor expression or 421 
immune components available. 422 
 423 
 424 
Figure 2: Systems serology data-driven modelling approaches 425 
Systems Serology involves running high-throughput experimental assays that measure Ab 426 
biophysical and functional data (X) in parallel with a functional or clinical outcomes (Y). 427 
Upon collation, the datasets can be interrogated by unsupervised and supervised machine 428 
learning computational techniques, including Principal Component Analysis (PCA), 429 
correlation networks, Partial Least Square Discriminant Analysis and Regression (PLSDA 430 
and PLSR), and decision trees. Correlation network figure was kindly contributed by Manu 431 
Kumar and Doug Lauffenburger (MIT). 432 
 433 
 434 
Table 1: Examples of functional antibodies in the control of infectious viral, bacterial, 435 



















Virus Bacteria Fungus Parasite 
ADCC HIV 12, 15, 18, 48, 49,50 
Influenza 51-53, 



























HIV 15, 17, 45. 
Influenza 63, 64
Salmonella 
paratyphi A  65
Clostridium 










































































































Smaller pathogen eg 
virus 
Larger pathogen eg 
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Immune complex assays 87, 88 
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IgG1 (6 alleles) 
IgG2 (1 allele) 
IgG3 (13 alleles) 







C1q, MBL, FcγRI, 
FcγRIIa, FcγRIIb, 
FcγRIIIa, FcRγIIIb, 
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